Sientra announced that it has begun commercial shipping of its Viality with AuraClens fat transfer system. The Company also announced the release of preliminary results from its on-going, multi-center, long-term volume retention clinical study with Viality. These preliminary results show over 80% volume retention at both the 3- and 6-month timepoints, making Viality the first, and only, system to have clinically demonstrated such high levels of retention. Based on the preliminary results, with 68 patients enrolled, the clinical study shows over 80% volume retention at both 3- and 6-months post breast augmentation and reconstruction. In addition, volume changes from 3 to 6 months were on average only 3.59%, indicating the long-term viability of fat transfer when using Viality.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SIEN: